4D pharma PLC Sponsored ADR LBPS

Market cap: $37.2M
P/E: 0.0×

Follow LBPS

Growth Flags show if company had growth for consecutive years

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions

in millions of $

	Nov 25			Feb 26			May 26			Aug 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 90.69%

Capital & Financial Ratios

Market Cap 37.19

Revenue 1.41

Net Income (135.64)

Free Cash Flow (88.99)

Net Debt (7.52)

Current Ratio 5.21

Debt/Equity 0.43

P/E ratio 0.00

P/S ratio 211.23

P/B ratio 9.49

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next 5Y EPS Growth —

in millions of $

Dividends

Payout Ratio 0.00

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2019	Powerpack

predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

	2018	2019	2020	2021
Cash	1	1	0	12
Receivables	7	7	7	5
Inventory	—	—	—	—
Other	0	1	4	3
	1	1	15	21

	2018	2019	2020	2021
Payables	0	0	2	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	0	0	6	9

in millions of $

Compound Annual Growth

	10y	5y	3y
Sales	—	21.70%	38.72%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	45.33%	1.30%

Revenue

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’21	—	—	—	0	1
’21	—	—	—	—	1
’20	—	—	—	—	1
’20	—	—	—	—	0
’19	—	—	—	—	0

in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

	Feb	May	Aug	Nov	Year
’26	—	—	—	—	—
’21	—	—	—	—	(38)
’21	(27)	—	—	—	(27)
’20	—	0	0	0	(27)
’20	(28)	—	—	—	(29)
’19	—	0	0	0	(29)
’19	—	—	—	—	0

in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

	Feb	May	Aug	Nov	Year
’26	—	—	—	—	—
’21	—	—	—	—	(38)
’21	(27)	—	—	—	(27)
’20	—	0	0	0	(27)
’20	(28)	—	—	—	(29)
’19	—	0	0	0	(29)
’19	—	—	—	—	0

in millions of $ · fiscal quarters ending in the months shown

EPS

	Feb	May	Aug	Nov	Year
’26	—	—	—	—	—
’21	—	—	—	—	(1.52)
’20	—	(0.06)	(0.10)	(0.10)	(2.34)
’20	(0.09)	—	—	—	(0.50)
’19	—	0.01	(0.07)	(0.06)	(0.46)
’19	—	—	—	—	—
’18	—	—	0.00	(0.01)	(3.86)

fiscal quarters ending in the months shown

value withheld pending a data check

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
—	—	—	—	—	—	—	—	—	—	Analyst estimates 2022–2024 Powerpack	Low Price
—	—	—	—	—	—	—	—	—	—		High Price
—	—	—	—	—	—	—	—	—	—		Employees
—	—	—	—	—	—	0	0	0	0		Revenue/Emp
—	—	—	—	—	—	0	0	1	1		Revenue
—	—	—	—	0.00%	0.00%	(572.40%)	100.00%	100.00%	100.00%		Gross Margin
—	—	—	—	(14)	(32)	0	(30)	(31)	(32)		EBT
—	—	—	—	0.00%	0.00%	(5.32%)	(11,276.21%)	(4,421.45%)	(4,451.25%)		EBT Margin
—	—	—	—	(12)	0	0	(30)	(30)	(32)		Net Income
—	—	—	—	1	1	0	2	2	1		Depreciation
—	—	—	—	0.00	0.00	0.03	0.00	0.05	0.03		Revenue/Sh
—	—	—	—	(0.19)	(0.42)	(3.86)	(0.46)	(2.34)	(1.52)		Earnings/Sh
—	—	—	—	(0.24)	(0.35)	(0.04)	(0.44)	(1.91)	(1.79)		Cash Flow/Sh
—	—	—	—	0.00	0.00	0.00	(0.01)	(0.02)	(0.01)		Capex/Sh
—	—	—	—	(0.24)	(0.35)	(0.04)	(0.45)	(1.93)	(1.80)		Free CF/Sh
—	—	—	—	1.65	1.45	0.61	0.48	2.73	1.53		Book Value/Sh
—	—	—	—	65	65	8	65	14	21		Shares
—	—	—	—	—	—	0.00	0.00	0.00	0.00		PE Ratio
—	—	—	—	—	—	0.00	0.00	0.00	697.71		PS Ratio
—	—	—	—	—	—	3.54	21.88	4.36	31.35		PB Ratio
—	—	—	—	—	—	0.00	0.00	0.00	692.37		EV/Sales
—	—	—	—	—	—	0.00	(14.97)	(3.57)	(10.81)		EV/FCF
—	—	—	—	(16)	(23)	0	(29)	(27)	(38)		Op' Cash Flow
—	—	—	—	(3)	(3)	0	(1)	0	0		Capex
—	—	—	—	(16)	(23)	0	(29)	(27)	(38)		FCF
—	—	—	—	86	71	1	8	12	28		Working Cap'
—	—	—	—	—	0	0	1	1	13		Total Debt
—	—	—	—	(85)	(68)	(1)	(4)	(11)	(8)		Net Debt
—	—	—	—	107	94	5	31	39	32		Sh' Equity
—	—	—	—	(11.07%)	(48.05%)	(0.07%)	(74.02%)	(67.82%)	(108.64%)		ROA
—	—	—	—	0.00%	0.00%	(6.27%)	(91.89%)	(77.94%)	(96.48%)		ROIC
—	—	—	—	(12.11%)	(27.48%)	(0.03%)	(167.65%)	(87.26%)	(89.48%)		ROE

predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Dec 2021 · latest quarter Dec 2021

Company	Market cap	P/E	Compare
BCTX BRIACELL THERAP	$37.2M	1.9×	Compare
ATNM Actinium Pharmaceuticals, Inc.	$37.4M	3.3×	Compare
FLNA Cassava Sciences, Inc.	$37.8M	0.0×	Compare
NNVC NanoViricides, Inc.	$38.0M	0.0×	Compare

Company	Market cap	P/E	Compare
CRVO CervoMed Inc.	$38.1M	0.0×	Compare
CELU Celularity, Inc.	$38.2M	0.0×	Compare
MCRB Seres Therapeutics, Inc.	$36.0M	0.0×	Compare
IMMP Prima BioMed Ltd	$38.5M	0.0×	Compare

All 616 Biotechnology stocks →